MMJ国际公司将符合FDA/DEA要求的稀有疾病类大麻素药物预付给FDA/DEA,寻求美国更快的监管批准以领导50B全球市场。 MMJ International advances FDA/DEA-compliant cannabinoid drugs for rare diseases, seeking faster U.S. regulatory approval to lead a $50B global market.

由Duane Boise领导的MMJ国际控股公司(MMJ International Holdings)正在推动对亨廷顿病和多发性硬化症等疾病进行符合林业发展局和药品管理局要求的药物级大麻素治疗,强调科学规范、GMP标准以及天然THC/CBD配方。 MMJ International Holdings, led by Duane Boise, is advancing FDA- and DEA-compliant, pharmaceutical-grade cannabinoid treatments for conditions like Huntington’s disease and multiple sclerosis, emphasizing scientific rigor, GMP standards, and natural THC/CBD formulations. 随着FDA的孤儿药品指认和IND申请被接受,该公司准备迅速扩大规模,等待药品管理局就散装制造登记采取行动。 With FDA Orphan Drug Designations and accepted IND applications, the company is poised for rapid scale-up pending DEA action on bulk-manufacturing registrations. 它呼吁进行联邦监管改革,以加快患者获得治疗的速度,并呼吁美国在预计到2030年全球500亿美元大麻素制药市场中发挥领导作用。 It calls for federal regulatory reforms to accelerate patient access and U.S. leadership in the projected $50 billion global cannabinoid pharmaceutical market by 2030.